Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry.
Keith A A FoxVictor AboyansE Sebastian DebusUwe ZeymerMartin R CowieManesh PatelRobert C WelshJackie BoschAlain GayKai VogtländerSonia S AnandPublished in: European heart journal. Cardiovascular pharmacotherapy (2022)
The characteristics of patients initiated on dual pathway inhibition (DPI: rivaroxaban 2.5 mg twice daily plus aspirin) have not previously been defined in clinical practice and the XATOA registry findings demonstrate patient outcomes are consistent with those of the COMPASS trial, despite geographic differences in recruitment and the higher proportion of PAD patients.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- clinical trial
- randomized controlled trial
- peritoneal dialysis
- type diabetes
- physical activity
- venous thromboembolism
- coronary artery disease
- patient reported outcomes
- metabolic syndrome
- skeletal muscle
- patient reported
- insulin resistance